QUOIN PHARMACEUTICALS LT-ADR
QNRXNASDAQTrading Snapshot
- Day Range
- $4.81 – $4.91
- 52-Week Range
- $3.25 – $41.80
- Volume
- $2.94B
- Avg Volume
- $3.56B
- Shares Outstanding
- 2.0M
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $757,295
- P/E Ratio
- -0.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-9.34
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +28021.7%
Why Investors Own QNRX
- ✓High-growth profile — revenue up +6.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 59% gross margin and 5% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
QUOIN PHARMACEUTICALS LT-ADR
QNRX
StockOtter · stockotter.spaceAbout QUOIN PHARMACEUTICALS LT-ADR
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy – Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome – Fast Track Designation Facilitates Development an
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
Quoin Pharmaceuticals releases a new NETHERTON NOW video featuring Laura Wright-Sexton, MD, who first met her daughter Aminah as a patient in the ICU.
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin M
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Second Rare Pediatric Disease (RPD) Designation for QRX003 FDA Previously Granted RPD Designation for QRX003 in Netherton Syndrome If a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin M
Quoin Pharmaceuticals Stock Surges Friday: What's Happening?
Shares of Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) are rallying Friday morning following back-to-back pre-market updates detailing positive clinical trial results and a major institutional financing package.
Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance Four of Six (66.7%) Participants Achieved the Targe